The development of adequate model systems to study human malignancies is crucial for basic and preclinical research. Here, we exploit the "immune-privileged" developmental time window to achieve orthotopic xenotransplantation of human brain tumor cells in wild-type (WT) mice. We find that, when transplanted in utero, human glioblastoma (GBM) cells readily integrate in the embryonic mouse brain mirroring key tumor-associated pathological features such as infiltration, vascularization, and complex tumor microenvironment including reactive astrocytes and host immune cell infiltration. Remarkably, activation of the host IBA1 tumor-associated microglia/macrophages depends on the type of glioma cell transplanted, suggesting our approach allows one to study human GBM interactions with the immune system of WT host mice. The embryonic engraftment model complements existing ones, providing a rapid and valuable alternative to study fundamental biology of human brain tumors in immune competent mice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957874 | PMC |
http://dx.doi.org/10.1016/j.isci.2019.100813 | DOI Listing |
Neurosurg Rev
January 2025
Department of Neurosurgery, Shiraz University of Medical Sciences, Shiraz, Iran.
Traumatic Brain Injury (TBI) is a devastating cause of death and disability. Outcomes following TBI have been extensively studied; however, less attention has been given to identifying characteristics of individuals who have a favorable outcome following severe TBI. We conducted a retrospective analysis of a database containing information on TBI patients admitted to a level 1 trauma center between 2015 and 2021.
View Article and Find Full Text PDFDiscov Oncol
January 2025
Department of Neurosurgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, 415003, Hunan, China.
Purpose: Glioma is the most prevalent tumor of the central nervous system. The poor clinical outcomes and limited therapeutic efficacy underscore the urgent need for early diagnosis and an optimized prognostic approach for glioma. Therefore, the aim of this study was to identify sensitive biomarkers for glioma.
View Article and Find Full Text PDFNat Commun
January 2025
British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.
Cheek swabs, heterogeneous samples consisting primarily of buccal epithelial cells, are widely used in pediatric DNA methylation studies and biomarker creation. However, the decrease in buccal proportion with age in adults remains unexamined in childhood. We analyzed cheek swabs from 4626 typically developing children 2-months to 20-years-old.
View Article and Find Full Text PDFEpigenetics Chromatin
January 2025
Univ Lyon, Université Lyon 1, INSERM, Stem Cell and Brain Research Institute U1208, INRAE USC 1361, Bron, F-69500, France.
Post-translational modifications of histone H3 on lysine 9, specifically acetylation (H3K9ac) and tri-methylation (H3K9me3), play a critical role in regulating chromatin accessibility. However, the role of these modifications in lineage segregation in the mammalian blastocyst remains poorly understood. We demonstrate that di- and tri-methylation marks, H3K9me2 and H3K9me3, decrease during cavitation and expansion of the rabbit blastocyst.
View Article and Find Full Text PDFCrit Care
January 2025
Brain Physics Laboratory, Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, Cambridge, UK.
Background: The oxygen reactivity index (ORx) reflects the correlation between focal brain tissue oxygen (pbtO) and the cerebral perfusion pressure (CPP). Previous, small cohort studies were conflicting on whether ORx conveys cerebral autoregulatory information and if it is related to outcome in traumatic brain injury (TBI). Thus, we aimed to investigate these issues in a larger TBI cohort.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!